Clinical trials
Primary Ovarian Insufficiency trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 20 |
| Completed | 7 |
| Recruiting | 6 |
| Not yet recruiting | 3 |
| Active, not recruiting | 2 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shi Yun | 4 |
| Chinese Academy of Sciences | 3 |
| International Peace Maternity and Child Health Hospital | 3 |
| Affiliated Hospital of Nantong University | 2 |
| Guangzhou University of Traditional Chinese Medicine | 2 |
| Li-jun Ding | 2 |
| Nanfang Hospital, Southern Medical University | 2 |
| Tongji Hospital | 2 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Fuda Cancer Hospital, Guangzhou | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Ovarian Insufficiency | 40 |
| Bone Diseases, Metabolic | 1 |
| Gynatresia | 1 |
| Infertility | 1 |
| Menopause, Premature | 1 |
| Menstruation Disturbances | 1 |
| Osteoarthritis | 1 |
Trials
Showing 26 to 40 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.